Angiolutions appoints leading international experts to its Medical Board
New board brings deep vascular and endovascular expertise to support development of the A³-Shield® System for abdominal aortic aneurysms
Share this on:
Hannover, Germany – April 20, 2026 – Angiolutions today announced the appointment of four internationally recognized vascular and endovascular specialists to its Medical Board. The new board will support the company as it advances development of its investigational A3-Shield® System, a first-in-class implant designed to treat abdominal aortic aneurysms (AAAs) by locally modulating aortic pulse waves.
The Angiolutions Medical Board brings together leading physicians from the United States and Europe with extensive clinical, scientific and translational expertise in vascular surgery, endovascular therapies and aortic disease management. The inaugural members are:
- Prof. Mark A. Farber – University of North Carolina at Chapel Hill (UNC), USA
- Prof. Tilo Kölbel – University Medical Center Hamburg, Germany
- Prof. Hubert Schelzig – University Medical Center Düsseldorf, Germany
- Prof. Peter Schneider – University of California, San Francisco (UCSF), USA
Photo caption: The Angiolutions medical Board: From left to right Prof. Mark A. Farber, Prof. Tilo Kölbel, Prof. Hubert Schelzig, Prof. Peter Schneider
“We are proud to welcome this outstanding group of physicians to the Angiolutions Medical Board,” said Dr. Isabel N. Schellinger, MD, Co-Founder & CEO of Angiolutions. “Their collective experience in vascular and endovascular care will be invaluable as we continue to develop the A3-Shield® System and generate clinical evidence for a new treatment approach in patients with small AAAs. By working closely with leading experts in the field, we aim to accelerate our mission to offer patients an earlier therapeutic option.”
The Medical Board will provide strategic clinical guidance across product development, clinical investigation and future adoption pathways as Angiolutions extends its clinical program. Its members will help inform Angiolutions’ efforts to address a major unmet need in AAA care: the lack of an active treatment option for patients with small aneurysms who are not eligible for conventional repair.
“Bringing together leading experts from renowned centers in the U.S. and Europe is an important step for Angiolutions,” said Dr. Uwe Raaz, MD, Co-Founder & CEO of Angiolutions. “Their insights will be of utmost importance in shaping clinical strategy as we work to redefine how abdominal aortic aneurysms can be treated at an earlier stage.
About Abdominal Aortic Aneurysm (AAA)
AAA is a highly prevalent, progressive dilation of the abdominal aorta. Although most AAAs are detected at a small size, current interventional treatments are generally reserved for large, advanced aneurysms due to their inherent risk profile. As a result, patients with small AAAs often face years of “watch and wait” follow‑up without an active treatment option. Angiolutions’ A3-Shield® will address this unmet need by introducing pulse wave modulation as new treatment approach to halt disease progression at an early stage.
A short animation demonstrating how the Angiolutions A3‑Shield® implant works:
You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationAbout Angiolutions
Angiolutions is a medical technology company pioneering a new treatment for abdominal aortic aneurysms (AAAs), a major vascular disease. Its A3-Shield® System is a first-in-class implant that stops AAA growth by locally modulating aortic pulse waves. The company is currently conducting its first-in-human clinical trial. Angiolutions is headquartered in Hannover, Germany. More information can be found on https://angiolutions.com
Disclaimer
2026 All rights reserved. The Angiolutions® A3‑Shield® System is an investigational device used exclusively for clinical investigation and not approved for commercial sale.